吸入短效β2受体激动剂治疗学龄前儿童急性喘息/哮喘症状的短期疗效:系统评价与Meta分析
该系统评价与Meta分析纳入19项研究共1022名6岁以下儿童,评估吸入短效β2受体激动剂(SABA)对急性喘息/哮喘症状的短期疗效。结果显示,吸入SABA可降低呼吸评分、呼吸频率、呼吸做功和喘息评分,并提高血氧饱和度,2岁以下亚组效果相似。但研究间异质性高且样本量小。
要点
- 吸入SABA可在60分钟内降低学龄前儿童急性喘息/哮喘的呼吸评分。
- 吸入SABA可降低呼吸频率、呼吸做功和喘息评分,并提高血氧饱和度。
- 2岁以下儿童亚组分析显示所有结局均有类似显著效果。
核心结论
- 吸入SABA治疗学龄前儿童及婴儿急性喘息/哮喘症状具有有益效果。
- 研究结果可为未来儿童及婴儿急性喘息/哮喘治疗指南提供证据支持。
研究设计与样本
- 系统评价与Meta分析,检索PubMed和Embase至2024年8月。
- 纳入19项临床试验,共1022名6岁以下儿童。
- 采用随机效应Meta分析,计算标准化均数差、95%CI和p值。
主要发现
- 呼吸评分在60分钟内下降:标准化均数差-2.05分(95%CI -2.50; -1.59),I2=86%,p<0.001,基于10项研究N=523。
- 呼吸频率下降:标准化均数差-0.86(95%CI -1.30; -0.41),I2=87%,p<0.001,基于8项研究N=319。
- 血氧饱和度升高:标准化均数差0.56(95%CI 0.16; 0.95),I2=71%,p<0.01,基于7项研究N=190。
- 呼吸做功下降:标准化均数差-0.80(95%CI -1.60; -0.00),I2=74%,p=0.05,基于3项研究N=68。
- 喘息评分下降:标准化均数差-1.07(95%CI -1.80; -0.33),I2=72%,p<0.01,基于3项研究N=68。
临床怎么用
- 对于学龄前儿童及婴儿急性喘息/哮喘症状,可考虑使用吸入SABA以快速改善呼吸状态。
- 2岁以下儿童使用吸入SABA同样可能获益。
局限性
- 研究间总体异质性高。
- 纳入研究的样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhaled short-acting β2-agonists (SABA) is recognised as an effective treatment in adults and older children with asthma, but the effect in young children and infants is still up for debate. We examine the efficacy of inhaled SABA for preschool-aged children presenting with acute wheeze/asthma in this systematic review and meta-analysis. METHODS: PubMed and Embase were searched through August 2024. Clinical trials investigating the effect of inhaled SABA on acute wheeze/asthma symptoms in children below age 6 years were included. The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Summary standardised mean differences, 95% CIs and p values were derived from random effects meta-analyses to analyse the effect on clinical composite respiratory score, respiratory rate, oxygen saturation, respiratory work and degree of wheezing. RESULTS: A total of 19 studies including 1022 children were included. Treatment with inhaled SABA showed decreased respiratory score within 60 min (10 studies, N=523): standardised mean difference -2.05 points (95% CI -2.50; -1.59), I2=86%, p<0.001, decreased respiratory rate (8 studies, N=319): -0.86 (95% CI -1.30; -0.41), I2=87%, p<0.001, increased oxygen saturation (7 studies, N=190): 0.56 (95% CI 0.16; 0.95), I2=71%, p<0.01, decreased respiratory work (3 studies, N=68): -0.80 (95% CI -1.60; -0.00), I2=74%, p=0.05 and decreased wheezing score (3 studies, N=68): -1.07 (95% CI -1.80; -0.33), I2=72%, p<0.01. Subgroup analyses of children below age 2 years showed similar significant effects for all outcomes. CONCLUSIONS: Inhaled SABA treatment for acute wheeze/asthma symptoms showed beneficial effects in young children and infants. Findings from this study may provide evidence to support inhaled SABA in future treatment guidelines for acute wheeze/asthma among young children and infants; however, an overall high heterogeneity and small sample size of the studies were a limitation. PROSPERO REGISTRATION NUMBER: CRD42023429381.
引用
- Storgaard Petersen, Hallas, Brustad, et al. Short-term efficacy of inhaled short-acting beta-2-agonists for acute wheeze/asthma symptoms in preschool-aged children: a systematic review and meta-analysis. Thorax. 2025. PMID: 40122609. doi:10.1136/thorax-2024-222760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。